Dominick & Dominick initiated coverage on Sarepta Therapeutics SRPT with a Market Perform rating.
Dominick & Dominick noted, "Sarepta Therapeutics, formerly known as AVI Biopharma, is developing RNA-based medicines that treat infectious and rare diseases at the molecular level. While we are enthusiastic regarding the recent encouraging data generated by the company's lead clinical program, eteplirsen (formerly known as AVI-4658) for Duchenne's Muscular Dystrophy (DMD), value-driving catalysts will be rekindled in 2014. As such, we believe the shares will mark time for the foreseeable future."
Sarepta Therapeutics closed at $31.01 on Monday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in